Autolus Therapeutics (NASDAQ:AUTL) Price Target Cut to $6.00 by Analysts at Wells Fargo & Company

Autolus Therapeutics (NASDAQ:AUTL) had its price objective cut by research analysts at Wells Fargo & Company from $8.00 to $6.00 in a report released on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective points to a potential upside of 252.94% from the stock’s previous close.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a report on Monday, January 13th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $9.52.

Autolus Therapeutics Trading Up 1.5 %

NASDAQ:AUTL opened at $1.70 on Friday. Autolus Therapeutics has a 1 year low of $1.56 and a 1 year high of $6.60. The firm has a 50 day moving average of $2.02 and a 200-day moving average of $2.91. The stock has a market capitalization of $452.36 million, a P/E ratio of -1.40 and a beta of 2.07.

Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $2.98 million. As a group, analysts forecast that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP increased its holdings in shares of Autolus Therapeutics by 4.6% in the fourth quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company’s stock valued at $59,562,000 after purchasing an additional 1,125,454 shares in the last quarter. FMR LLC grew its holdings in Autolus Therapeutics by 44.6% during the 3rd quarter. FMR LLC now owns 17,773,873 shares of the company’s stock worth $64,519,000 after acquiring an additional 5,478,706 shares during the period. TFG Asset Management GP Ltd grew its holdings in Autolus Therapeutics by 3.1% during the 4th quarter. TFG Asset Management GP Ltd now owns 8,250,000 shares of the company’s stock worth $19,388,000 after acquiring an additional 250,000 shares during the period. Candriam S.C.A. acquired a new stake in Autolus Therapeutics during the 4th quarter worth $7,500,000. Finally, AXA S.A. acquired a new stake in Autolus Therapeutics during the 4th quarter worth $4,288,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.